MRKR
Marker Therapeutics, Inc.Company Information
- Company Name
- Marker Therapeutics, Inc.
- CIK
- CIK0001094038
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- MRKR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MRKR
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-23
- Last sale
- —
- Shares purchased (TTM)
- 565,335
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 3,958,447
- Shares outstanding
- 19,314,742
- Ownership
- 20.49%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 3.51%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 11 | 15 | 16 | 18 | 10 | 14 | 19 | 9 | 8 | 11 | 15 | 17 | ||||||
| Restricted Cash Current | 1 | 1 | 1 | 1 | 1 | - | 0 | - | - | - | - | - | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | 0 | 1 | 1 | 1 | 1 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 0 | - | - | - | 1 | - | - | - | - | - | - | ||||||
| Other Receivables Net Current | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 0 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Assets Current | 15 | 17 | 19 | 22 | 15 | 17 | 22 | 11 | 12 | 14 | 17 | 19 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Assets | 15 | 17 | 19 | 22 | 15 | 17 | 22 | 11 | 12 | 14 | 17 | 19 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | ||||||
| Deferred Revenue Current | - | - | 1 | 1 | 1 | - | - | - | - | - | - | 0 | ||||||
| Other Liabilities Current | 1 | 1 | - | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | ||||||
| Liabilities Current | 2 | 4 | 2 | 3 | 4 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities | 2 | 4 | 2 | 3 | 4 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Additional Paid In Capital | 476 | 476 | 476 | 476 | 466 | 466 | 466 | 451 | 451 | 450 | 450 | 450 | ||||||
| Retained Earnings Accumulated Deficit | -464 | -462 | -459 | -457 | -455 | -451 | -447 | -443 | -441 | -439 | -436 | -433 | ||||||
| Stockholders Equity | 12 | 14 | 17 | 18 | 10 | 14 | 19 | 7 | 10 | 12 | 14 | 17 | ||||||
| Liabilities And Stockholders Equity | 15 | 17 | 19 | 22 | 15 | 17 | 22 | 11 | 12 | 14 | 17 | 19 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 130 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | ||||||
| Common Stock Shares Issued | 17 | 17 | 17 | 17 | 11 | 11 | 11 | 9 | 9 | 9 | 9 | 9 | ||||||
| Shares Outstanding | 17 | 17 | 17 | 17 | 11 | 11 | 11 | 9 | 9 | 9 | 9 | 9 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMarker Therapeutics, Inc. (MRKR) — SEC Financial Statements & Analysis
Marker Therapeutics, Inc. (MRKR) is a pharmaceutical preparations company, incorporated in DE. Marker Therapeutics, Inc. trades on Nasdaq as: MRKR. Marker Therapeutics, Inc. (MRKR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Marker Therapeutics, Inc. carries a market cap of $28.39M, a P/E ratio of -3.26x, a P/B ratio of 2.33x, a P/S ratio of 9.19x, an enterprise value of $16.47M, and an EV/EBITDA multiple of -1.73x. On profitability, it posts an operating margin of -307.74%, a net margin of -281.97%, a Return on Equity (ROE) of -76.87%, a Return on Assets (ROA) of -59.33%, and a Return on Invested Capital (ROIC) of -1873.81%. Per share, it reports EPS of $-0.45, diluted EPS of $-0.45, free cash flow per share of $-0.51, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -42.69% year-over-year, net income growth of -40.39% year-over-year, and EPS growth of -56.93% year-over-year. On the balance sheet, it maintains a current ratio of 6.03x, a quick ratio of 5.60x, working capital of $12.17M, a debt-to-equity ratio of 0.20x, a debt ratio of 0.17, free cash flow of $-9.76M (TTM), and net debt of $-11.92M. Figures sourced from SEC EDGAR.
- Market Cap
- $28.39M
- P/E TTM
- -3.26x
- EPS TTM
- $-0.45
- P/B TTM
- 2.33x
- ROE TTM
- -76.87%
- ROA TTM
- -59.33%
- Debt To Equity
- 0.20x
- Free Cash Flow TTM
- $-9.76M
- Net Revenue TTM Growth 1Y
- -42.69%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Marker Therapeutics, Inc. in?
Marker Therapeutics, Inc. (MRKR) operates in the Pharmaceutical Preparations industry.
What exchange does MRKR trade on?
Marker Therapeutics, Inc. (MRKR) trades on the Nasdaq.
Where is Marker Therapeutics, Inc. incorporated?
Marker Therapeutics, Inc. is incorporated in DE.
When was Marker Therapeutics, Inc. (MRKR)'s most recent SEC filing?
Marker Therapeutics, Inc. (MRKR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is MRKR's market cap?
Marker Therapeutics, Inc. (MRKR) has a market capitalization of $28.39M as of 2026-06-30.
What is MRKR's EPS (earnings per share)?
Marker Therapeutics, Inc. (MRKR)'s trailing twelve month EPS is $-0.45 as of 2026-06-30.
What is MRKR's ROE (return on equity)?
Marker Therapeutics, Inc. (MRKR)'s trailing twelve month Return on Equity (ROE) is -76.87% as of 2026-06-30.
What is MRKR's ROA (return on assets)?
Marker Therapeutics, Inc. (MRKR)'s trailing twelve month Return on Assets (ROA) is -59.33% as of 2026-06-30.
What is MRKR's ROIC (return on invested capital)?
Marker Therapeutics, Inc. (MRKR)'s trailing twelve month Return on Invested Capital (ROIC) is -1873.81% as of 2025-03-31.
What is MRKR's EV/EBITDA?
Marker Therapeutics, Inc. (MRKR)'s trailing twelve month EV/EBITDA is -1.73x as of 2026-06-30.